Dr. Finn on Current and Emerging Agents in the Field of HCC

Richard Finn, MD
Published: Friday, Sep 15, 2017



Richard Finn, MD, associate professor of medicine at the UCLA David Geffen School of Medicine, shares insight on some current and emerging agents in the field of hepatocellular carcinoma (HCC).

The field has recently seen promising data and an FDA approval of regorafenib (Stivarga) in the second-line setting of HCC treatment, Finn explains. At the 2017 International Liver Cancer Association Annual Conference, updated overall survival (OS) data on the phase III RESORCE trial, which compared regorafenib with placebo, will also be presented. 

Additionally, there is an emerging role for immunotherapy in this field, Finn adds. Nivolumab (Opdivo) is also being explored in an ongoing phase III trial, which has previously shown encouraging activity. FGFR4 inhibitors are also demonstrating early promise; early data are beginning to show clinical activity in a biomarker-selected population of patients with liver cancer. 

Brought to you in part by Eisai


Richard Finn, MD, associate professor of medicine at the UCLA David Geffen School of Medicine, shares insight on some current and emerging agents in the field of hepatocellular carcinoma (HCC).

The field has recently seen promising data and an FDA approval of regorafenib (Stivarga) in the second-line setting of HCC treatment, Finn explains. At the 2017 International Liver Cancer Association Annual Conference, updated overall survival (OS) data on the phase III RESORCE trial, which compared regorafenib with placebo, will also be presented. 

Additionally, there is an emerging role for immunotherapy in this field, Finn adds. Nivolumab (Opdivo) is also being explored in an ongoing phase III trial, which has previously shown encouraging activity. FGFR4 inhibitors are also demonstrating early promise; early data are beginning to show clinical activity in a biomarker-selected population of patients with liver cancer. 

Brought to you in part by Eisai

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x